Recombinant human epidermal growth factor receptor (EGFR) protein bearing the clinically relevant T790M and L858R mutations, expressed in Sf9 insect cells and supplied as a 0.22 μm filtered solution formulated in 50 mM HEPES pH 7.5, 200 mM NaCl, 20% glycerol, 5 mM DTT, and 0.1 M trehalose. The preparation is intended for biochemical and binding studies and has low endotoxin levels suitable for sensitive assays.
- Recombinant human EGFR containing T790M and L858R mutations.
- Expressed in Sf9 insect cells for eukaryotic post-translational processing.
- Supplied as a filtered, stabilized protein solution for immediate use.
- Formulated with glycerol and reducing agent to maintain stability.
- Low endotoxin level (<1 EU/μg) suitable for sensitive applications.